New combo therapy targets Platinum-Resistant ovarian cancer

NCT ID NCT04516447

Recruiting now Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive different drug combinations to find the safest dose and check for side effects. The goal is to control the disease, not cure it, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma peritoneum cancer primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER PERITONEAL CANCER SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 0103
RECRUITING

Houston, Texas, 77030, United States
Site 0104
RECRUITING

Boston, Massachusetts, 02215, United States
Site 0111
RECRUITING

St Louis, Missouri, 53110, United States
Site 0173
RECRUITING

New York, New York, 10029, United States
Site 0191
RECRUITING

Providence, Rhode Island, 02905, United States
Site 0196
COMPLETED

Nashville, Tennessee, 37203, United States
Site 0259
RECRUITING

Durham, North Carolina, 27710, United States
Site 0264
RECRUITING

Aurora, Colorado, 80045, United States
Site 1001
COMPLETED

Banja Luka, 78000, Bosnia and Herzegovina
Site 1002
COMPLETED

Sarajevo, 71000, Bosnia and Herzegovina
Site 1003
COMPLETED

Tuzla, 75000, Bosnia and Herzegovina
Site 1201
COMPLETED

Sofia, 1632, Bulgaria
Site 1202
COMPLETED

Panagyurishte, 4500, Bulgaria
Site 1401
COMPLETED

Tbilisi, 0112, Georgia
Site 1902
COMPLETED

Belgrade, 11080, Serbia
Site 2705
RECRUITING

Nedlands, Western Australia, 6009, Australia
Site 2706
RECRUITING

Melbourne, Victoria, 3144, Australia
Site 2707
COMPLETED

South Brisbane, Queensland, 4101, Australia
Site 2708
COMPLETED

Sunshine Coast, Queensland, 4556, Australia
Site 2709
COMPLETED

Adelaide, South Australia, 5000, Australia
Site 2716
RECRUITING

Melbourne, Victoria, 3121, Australia
Site 2901
COMPLETED

Busan, South Korea
Site 2903
COMPLETED

Seoul, 03080, South Korea
Site 2904
COMPLETED

Seoul, 05505, South Korea